Telaprevir
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors. Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3/4A serine protease. See also [https://en.wikipedia.org/wiki/Telaprevir]. | Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors. Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3/4A serine protease. See also [https://en.wikipedia.org/wiki/Telaprevir]. | ||
| + | <scene name='96/969645/Overall/1'>Crystal structure of NS3/4A protease in complex with Telaprevir</scene> ([[3sv6]]). | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 12:02, 12 June 2023
| |||||||||||
